University of Groningen
RPPA-profiling in pediatric acute leukemia: pattern recognition and therapeutic guidance Hoff, Fieke
DOI:
10.33612/diss.168765254
IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.
Document Version
Publisher's PDF, also known as Version of record
Publication date: 2021
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
Hoff, F. (2021). RPPA-profiling in pediatric acute leukemia: pattern recognition and therapeutic guidance. University of Groningen. https://doi.org/10.33612/diss.168765254
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.
- Pediatric acute leukemia could be classified into a limited number of protein expression signatures based on recurrent patterns in protein expression, that could enhance outcome risk stratification when combined with known risk-stratifiers
- Low-HSF1-pSer326 is a favorable prognostic protein in patients treated with bortezomib-containing chemotherapy. Addition of bortezomib to standard chemotherapy significantly improves outcome in
low-HSF1-pSer326 pediatric AML patients - The successful translation of the discoveries into effective therapy that improves outcome, critically dependents on having the ability to match patients on an individualized basis to the correct therapy - Protein expression profiles are associated with Hispanic ethnicity in ALL suggesting that pathophysiological differences likely exist - Protein expression signatures in APL are associated with relapse, suggesting that high-risk APL patients could potentially be identified based on their proteomic profiles - Mycoplasma infection of leukemic cell lines alters protein expression levels, potentially confounding
experimental results, reinforcing the need for regular testing of mycoplasma - Development of the sum of extremes methods provides a novel means for assessing samples with previously unrecognized quality control issues for exclusion from analysis
